Li et al. (2014) also reported on the effects of metformin in inhibiting the IL-6/STAT3 signaling pathway, reversing epithelial–mesenchymal transition (EMT), and overcoming EGFR-TKI drug (gefitinib and erlotinib) resistance in NSCLC cells. However, most relevant studies have been conducted in vitro and in vivo, and the mechanisms are still unclear. The gene discussed is IL6; the disease is non-small cell lung carcinoma.